[go: up one dir, main page]

CL2014000082A1 - Metodo para generar inmunidad protectora contra los norovirus en un ser humano mediante la administracion via parenteral de una unica dosis de una vacuna que comprende particulas tipo virus (vlp) del genogrupo i o ii de norovirus. - Google Patents

Metodo para generar inmunidad protectora contra los norovirus en un ser humano mediante la administracion via parenteral de una unica dosis de una vacuna que comprende particulas tipo virus (vlp) del genogrupo i o ii de norovirus.

Info

Publication number
CL2014000082A1
CL2014000082A1 CL2014000082A CL2014000082A CL2014000082A1 CL 2014000082 A1 CL2014000082 A1 CL 2014000082A1 CL 2014000082 A CL2014000082 A CL 2014000082A CL 2014000082 A CL2014000082 A CL 2014000082A CL 2014000082 A1 CL2014000082 A1 CL 2014000082A1
Authority
CL
Chile
Prior art keywords
vlp
vaccine
virus
particles
human
Prior art date
Application number
CL2014000082A
Other languages
English (en)
Inventor
Charles Richardson
Robert F Bargatze
Paul M Mendelman
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000082(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CL2014000082A1 publication Critical patent/CL2014000082A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CL2014000082A 2011-07-11 2014-01-10 Metodo para generar inmunidad protectora contra los norovirus en un ser humano mediante la administracion via parenteral de una unica dosis de una vacuna que comprende particulas tipo virus (vlp) del genogrupo i o ii de norovirus. CL2014000082A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161506447P 2011-07-11 2011-07-11

Publications (1)

Publication Number Publication Date
CL2014000082A1 true CL2014000082A1 (es) 2014-07-04

Family

ID=47506489

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000082A CL2014000082A1 (es) 2011-07-11 2014-01-10 Metodo para generar inmunidad protectora contra los norovirus en un ser humano mediante la administracion via parenteral de una unica dosis de una vacuna que comprende particulas tipo virus (vlp) del genogrupo i o ii de norovirus.

Country Status (29)

Country Link
US (5) US9801934B2 (es)
EP (3) EP2731621B1 (es)
JP (2) JP6208659B2 (es)
KR (1) KR102096937B1 (es)
CN (3) CN105031637A (es)
AU (2) AU2012282658B2 (es)
BR (1) BR112014000656A2 (es)
CA (1) CA2841356C (es)
CL (1) CL2014000082A1 (es)
CR (2) CR20190540A (es)
DK (1) DK3299030T3 (es)
DO (2) DOP2014000004A (es)
EA (3) EA202090699A3 (es)
EC (1) ECSP14013201A (es)
ES (2) ES2656527T3 (es)
GE (1) GEP201706668B (es)
HK (2) HK1199202A1 (es)
IL (1) IL230356B (es)
MA (1) MA35414B1 (es)
MX (2) MX379496B (es)
MY (1) MY170746A (es)
PE (1) PE20140845A1 (es)
PH (3) PH12021551773A1 (es)
PL (2) PL2731621T3 (es)
SG (1) SG10201605644WA (es)
TN (1) TN2014000008A1 (es)
UA (1) UA117732C2 (es)
WO (1) WO2013009849A1 (es)
ZA (2) ZA201401012B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2641613A1 (en) 2006-09-29 2013-09-25 Ligocyte Pharmaceuticals, Inc. Liquid norovirus vaccine formulations comprising toll-like receptor (TLR) agonist as adjuvant
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
CA2841356C (en) 2011-07-11 2022-03-01 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
CA2926225A1 (en) 2013-10-03 2015-04-09 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
JP6556632B2 (ja) 2013-12-16 2019-08-07 武田薬品工業株式会社 マイクロニードル
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en) 2017-03-07 2017-04-19 Elopak As Improvements in or relating to toller mounting arrangements
CA3061678A1 (en) * 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3752185A1 (en) * 2018-02-15 2020-12-23 Icon Genetics GmbH Immunogenic composition and vaccine for generating an immune response to norovirus
US20210121511A1 (en) * 2018-05-29 2021-04-29 Unm Rainforest Innovations Virus-like particle compositions and methods of using same
CN109265542B (zh) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
WO2021140524A1 (en) 2020-01-08 2021-07-15 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof
US20240156942A1 (en) 2021-03-29 2024-05-16 Denka Company Limited Peptide of Norovirus Origin, Polynucleotide, Antibody, Composition, Method for Identifying Neutralizing Epitope for Norovirus
US20240238401A1 (en) 2021-05-21 2024-07-18 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025077799A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Method of preparing norovirus vaccine without adjuvant
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
CA2133339A1 (en) 1992-04-08 1993-10-09 Jennifer S. Rota Wild-type measles virus glycoproteins: vaccine and detection method therefor
JPH08500250A (ja) 1992-09-07 1996-01-16 ベイラー・カレッジ・オブ・メディシン ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬
CN1087176C (zh) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
CN1152935A (zh) 1994-05-16 1997-06-25 麦克公司 乳头状瘤病毒疫苗
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
PT973546E (pt) 1997-04-08 2004-06-30 Merck & Co Inc Formulacoes estabilizadas de virus de papiloma humano
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
SK2232001A3 (en) 1998-08-14 2001-08-06 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
EP1140161B1 (en) 1998-12-17 2006-04-19 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
PT1150712E (pt) * 1999-02-05 2008-12-22 Merck & Co Inc Formulações para a vacina do vírus do papiloma humano
CA2783140C (en) 1999-06-22 2016-07-26 Japan As Represented By Directors-General National Institute Of Infectious Diseases Srsv detection kit
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US20040121465A1 (en) 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
AU2003247337B2 (en) 2002-04-11 2007-09-06 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CA2486118A1 (en) 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
MXPA04011210A (es) 2002-06-20 2005-02-14 Cytos Biotechnology Ag Particulares similares a virus empacadas para uso como adyuvantes: metodo de preparacion y uso.
CA2514667C (en) 2003-01-30 2013-01-08 Chiron Corporation Adjuvanted influenza vaccine
WO2004073652A2 (en) 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
EP1670824A2 (en) 2003-09-24 2006-06-21 Montana State University Norovirus monoclonal antibodies and peptides
US7795242B2 (en) 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
CA2584228C (en) 2004-10-20 2015-05-05 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
JP2008526870A (ja) 2005-01-05 2008-07-24 フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン 送達ビヒクル、生体作用活性物質およびウイルスワクチン
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
EP1858919B1 (en) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
ES2424229T3 (es) 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas
JP2009501001A (ja) 2005-06-01 2009-01-15 ダウ グローバル テクノロジーズ インコーポレイティド 多価ウイルス様粒子の製造
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
US20080029915A1 (en) * 2006-08-02 2008-02-07 Courtoy Nv Rotary tablet press
EP2641613A1 (en) 2006-09-29 2013-09-25 Ligocyte Pharmaceuticals, Inc. Liquid norovirus vaccine formulations comprising toll-like receptor (TLR) agonist as adjuvant
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
WO2008113011A2 (en) * 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
WO2009033229A1 (en) 2007-09-12 2009-03-19 Australian Centre For Plant Functional Genomics Pty Ltd Plant seed active transcriptional control sequences
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG10201601660YA (en) * 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
ES2668836T3 (es) 2008-08-08 2018-05-22 Takeda Vaccines, Inc. Partículas similivíricas que comprenden secuencias de aminoácidos de la cápside compuestas para reactividad cruzada potenciada
CA2750321A1 (en) * 2009-01-22 2010-07-29 Pharmathene, Inc. Stable vaccine compositions and methods of use
EP2942062A1 (en) * 2009-02-10 2015-11-11 Novartis AG Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
SG182636A1 (en) 2010-01-21 2012-08-30 Ligocyte Pharmaceuticals Inc Targeted heterologous antigen presentation on calicivirus virus-like particles
NO2575876T3 (es) * 2010-05-26 2018-05-05
CA2841356C (en) 2011-07-11 2022-03-01 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
DK3827838T5 (en) 2015-12-16 2024-08-19 Walter & Eliza Hall Inst Medical Res Hæmning af cytokin-induceret sh2-protein i nk-celler
GB2605540B (en) 2016-10-18 2022-12-21 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
NZ770183A (en) 2018-05-03 2025-05-02 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
EP3840778A1 (en) 2018-08-20 2021-06-30 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
PH12021552003A1 (en) 2019-02-15 2022-12-05 Editas Medicine Inc Modified natural killer (nk) cells for immunotherapy

Also Published As

Publication number Publication date
DOP2014000004A (es) 2014-10-31
EA201792407A3 (ru) 2018-07-31
EA202090699A2 (ru) 2020-07-31
WO2013009849A1 (en) 2013-01-17
US10675341B2 (en) 2020-06-09
IL230356B (en) 2019-05-30
EP2731621B1 (en) 2017-11-01
EP3299030B1 (en) 2022-06-08
CN105031637A (zh) 2015-11-11
HK1199202A1 (en) 2015-06-26
US11701420B2 (en) 2023-07-18
PH12014500093A1 (en) 2014-03-17
KR102096937B1 (ko) 2020-04-03
AU2012282658B2 (en) 2014-11-27
ZA201500915B (en) 2016-06-29
SG10201605644WA (en) 2016-09-29
JP6208659B2 (ja) 2017-10-04
CR20140069A (es) 2014-06-27
US20180185468A1 (en) 2018-07-05
US20160000899A1 (en) 2016-01-07
DOP2022000030A (es) 2022-06-30
CA2841356C (en) 2022-03-01
UA117732C2 (uk) 2018-09-25
PL2731621T3 (pl) 2018-10-31
CR20190540A (es) 2022-04-04
EP3299030A1 (en) 2018-03-28
PE20140845A1 (es) 2014-08-03
MA35414B1 (fr) 2014-09-01
PH12021551773A1 (en) 2022-08-01
TN2014000008A1 (en) 2015-07-01
DK3299030T3 (da) 2022-09-05
AU2015200836A1 (en) 2015-03-12
CN108567975A (zh) 2018-09-25
JP2014520852A (ja) 2014-08-25
NZ620865A (en) 2015-08-28
ES2926487T3 (es) 2022-10-26
HK1215154A1 (zh) 2016-08-19
HK1198136A1 (en) 2015-03-13
JP6613259B2 (ja) 2019-11-27
US20230338503A1 (en) 2023-10-26
EP4112074A1 (en) 2023-01-04
JP2017214357A (ja) 2017-12-07
US9801934B2 (en) 2017-10-31
CN103874507A (zh) 2014-06-18
GEP201706668B (en) 2017-05-25
MY170746A (en) 2019-08-27
US20210085778A1 (en) 2021-03-25
PH12018501515B1 (en) 2022-02-18
EA201490258A1 (ru) 2014-05-30
MX2014000411A (es) 2014-08-26
PL3299030T3 (pl) 2022-12-05
AU2012282658A1 (en) 2013-03-14
US20130273102A1 (en) 2013-10-17
EA201792407A2 (ru) 2018-03-30
MX379496B (es) 2025-03-11
EA029470B1 (ru) 2018-03-30
EA035442B1 (ru) 2020-06-17
EP2731621A1 (en) 2014-05-21
CA2841356A1 (en) 2013-01-17
MX356586B (es) 2018-06-05
NZ710919A (en) 2017-12-22
BR112014000656A2 (pt) 2017-02-14
ZA201401012B (en) 2015-05-27
KR20140066160A (ko) 2014-05-30
EA202090699A3 (ru) 2020-11-30
AU2015200836B2 (en) 2016-08-25
ECSP14013201A (es) 2014-05-31
US9867876B2 (en) 2018-01-16
PH12018501515A1 (en) 2019-02-04
EP2731621A4 (en) 2015-03-25
ES2656527T3 (es) 2018-02-27

Similar Documents

Publication Publication Date Title
CL2014000082A1 (es) Metodo para generar inmunidad protectora contra los norovirus en un ser humano mediante la administracion via parenteral de una unica dosis de una vacuna que comprende particulas tipo virus (vlp) del genogrupo i o ii de norovirus.
MX383065B (es) Mutantes de virus de influenza y usos para los mismos.
CO2017004119A2 (es) Partículas tipo virus modificadas de cmv
CL2014001110A1 (es) Compuestos derivados de piperazin-piridin-bifenil-imidazol-pirrolidinas sustituidas, inhibidores de la replicacion del virus de la hepatitis c (hcv); composicion farmaceutica que los comprende; proceso para preparar un compuesto; metodo para tratar una infeccion del virus hcv; y uso para tratar una infeccion del virus hcv.
CR20140189S (es) Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue
CL2014000245A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de replicacion de los virus de influenza; metodo de preparacion; composicionn farmaceutica; metodo para inhibir la replicacion del virus de la influenza en una muestra biológica o un paciente.
BR112014010545A2 (pt) composição farmacêutica, método para tratar um paciente infectado com vírus da hepatite c, uso de uma composição
BR112014001049A2 (pt) método para a produção de um antígeno viral derivado de vírus envelopado, e, uso de um método para a fabricação de uma preparação de vacina contendo o antígeno viral
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
CU20180025A7 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
MX388525B (es) Métodos mejorados para inactivación de enterovirus, composiciones de vacuna con adsorción de adyuvante y reducida en dosis obtenida de los mismos.
BR112012016048A2 (pt) "exossomas derivados de reticulócitos infectados com plasmodium sp., método para obter os mesmos e usos dos mesmos".
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
CL2014003012A1 (es) Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c.
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
DK201370530A (en) Salmonid alphavirus vaccine
DK2739725T3 (da) Fremgangsmåde til oprensning af virus-lignende partiker (vlp)
BR112015019619A2 (pt) métodos para liberação e para purificação de partículas tipo vírus expressadas por baculovírus de vírus não encapsulados
CR20150246A (es) Composición inmunogénica contra la aeromonas hydrophila
CL2015000037A1 (es) Metodo de alta eficiencia para purificar particulas similares a virus del virus del papiloma humano.
MX385188B (es) Vacuna de rinitis equina.
CU20150019A7 (es) Rotavirus humanos modificados
ES1141483Y (es) Aparato para la preparación de infusiones de café, u otra sustancia, mediante vaina o capsula de una dosis, por microondas
IN2014MN02275A (es)
CL2014000687A1 (es) Proceso para preparar una sal de cinconidina, inhibidor macrociclico de la proteasa del virus de la hepatitis c (hvc).